Managing SG&A Costs: A Tale of Two Companies

In the competitive landscape of biotechnology and medical devices, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. CRISPR Therapeutics AG and MiMedx Group, Inc. offer a fascinating study in contrasts over the past decade.

A Decade of Financial Strategy

From 2014 to 2023, MiMedx Group, Inc. consistently reported higher SG&A expenses, peaking at over $258 million in 2018. In contrast, CRISPR Therapeutics AG's expenses grew from a modest $5 million in 2014 to a high of approximately $103 million in 2021. This represents a staggering 1,900% increase, reflecting their aggressive expansion and investment in innovation.

Efficiency vs. Expansion

While MiMedx's expenses remained relatively stable, CRISPR's rapid growth suggests a strategic focus on scaling operations. Investors and analysts should consider these trends when evaluating each company's operational efficiency and long-term viability.